Module 5: Additional Resources

Federal Response to COVID-19: Therapeutics Clinical Implementation Guide (Outpatient Administration Guide for Healthcare Providers)

COVID-19 Vaccination after mAb Administration

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the US

Non-hospitalized COVID-19 patients who previously received passive antibody therapy
There is no longer any need to delay vaccination following receipt of monoclonal antibody or convalescent plasma beyond recovery from the acute illness (if symptoms were present) and criteria to discontinue isolation have been met.
Hospitalized COVID-19 patients

Follow guidelines from CDC Advisory Committee on Immunization Practices

Reporting Cadence

For sotrovimab,
bam/ete, REGEN-COV,
bebtelovimab, Evusheld

HPOP icon

Reporting required
once a month by 11:59ET pm the last day of the month

For
Paxlovid
and Lagevrio

HPOP icon

Reporting required at least twice a month by 11:59ET pm on the 15th and last day of the month

Sites with inventory of USG-purchased COVID-19 therapeutics must provide information on product utilization, wastage and stock on hand

COVID-19 Therapeutic Resources

Administration for Strategic Preparedness and Response
For the latest information on all COVID-19 therapeutics, refer to:

Still have questions? Reach out to HHS COVID 19 Therapeutics Email covid19therapeutics@hhs.gov

CIG Right-Nav

Introduction

Module 1: COVID-19 Outpatient Therapeutics Overview

Module 2: Product Information

Module 3: Oral Antiviral Administration

Module 4: Reimbursement

Module 5: Additional Resources

Module 6: Appendices